The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia

被引:75
作者
Duman, Dildar [1 ]
Aksoy, Emine [1 ]
Agca, Meltem Coban [1 ]
Kocak, Nagihan Durmus [1 ]
Ozmen, Ipek [1 ]
Akturk, Ulku Aka [1 ]
Gungor, Sinem [1 ]
Tepetam, Fatma Merve [1 ]
Eroglu, Selma Aydogan [1 ]
Oztas, Selahattin [1 ]
Karakurt, Zuhal [1 ]
机构
[1] Sureyyapasa Chest Dis & Thorac Surg Teaching Hosp, Istanbul, Turkey
来源
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2015年 / 10卷
关键词
chronic obstructive pulmonary disease; exacerbation; peripheral eosinophilia; mortality; OBSTRUCTIVE PULMONARY-DISEASE; MEAN PLATELET VOLUME; RANDOMIZED CONTROLLED-TRIAL; C-REACTIVE PROTEIN; LYMPHOCYTE RATIO; ACUTE EXACERBATION; NEUTROPHIL; BIOMARKERS; THERAPY; PREDNISOLONE;
D O I
10.2147/COPD.S90330
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: COPD exacerbations requiring hospitalization increase morbidity and mortality. Although most COPD exacerbations are neutrophilic, approximately 10%-25% of exacerbations are eosinophilic. Aim: We aimed to evaluate mortality and outcomes of eosinophilic and non-eosinophilic COPD exacerbations and identify new biomarkers that predict survival. Methods: A retrospective observational cohort study was carried out in a tertiary teaching hospital from January 1, 2014 to November 1, 2014. All COPD patients hospitalized with exacerbations were enrolled in the study at their initial hospitalization and followed-up for 6 months after discharge. Electronic data were collected from the hospital database. Subjects' characteristics, hemogram parameters, CRP levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-mean platelet volume ratio on admission and discharge, length of hospital stay (days), readmissions, and mortality were recorded. Patients were grouped according to peripheral blood eosinophil (PBE) levels: Group 1, >2% PBE, eosinophilic; Group 2, non-eosinophilic <= 2%. Patient survival after hospital discharge was evaluated by Kaplan-Meier survival analysis. Results: A total of 1,704 patients hospitalized with COPD exacerbation were included. Approximately 20% were classified as eosinophilic. Six-month mortality was similar in eosinophilic and non-eosinophilic groups (14.2% and 15.2%, respectively); however, the hospital stay length and readmission rate were longer and higher in the non-eosinophilic group (P<0.001 and P<0.01, respectively). CRP and NLR were significantly higher in the non-eosinophilic group (both P<0.01). The platelet-to-mean platelet volume ratio was not different between the two groups. Cox regression analysis showed that survival was negatively influenced by elevated CRP (P<0.035) and NLR (P<0.001) in the non-eosinophilic group. Conclusion: Non-eosinophilic patients with COPD exacerbations with high CRP and NLR values had worse outcomes than eosinophilic patients. PBE and NLR can be helpful markers to guide treatment decisions.
引用
收藏
页码:2469 / 2478
页数:10
相关论文
共 36 条
[1]  
[Anonymous], GLOB STRAT DIAGN MAN
[2]   ANTIBIOTIC-THERAPY IN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE [J].
ANTHONISEN, NR ;
MANFREDA, J ;
WARREN, CPW ;
HERSHFIELD, ES ;
HARDING, GKM ;
NELSON, NA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (02) :196-204
[3]   C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations [J].
Antonescu-Turcua, Andreea L. ;
Tomic, Rade .
CURRENT OPINION IN PULMONARY MEDICINE, 2009, 15 (02) :120-125
[4]   Profiling of Sputum Inflammatory Mediators in Asthma and Chronic Obstructive Pulmonary Disease [J].
Bafadhel, M. ;
McCormick, M. ;
Saha, S. ;
McKenna, S. ;
Shelley, M. ;
Hargadon, B. ;
Mistry, V. ;
Reid, C. ;
Parker, D. ;
Dodson, P. ;
Jenkins, M. ;
Lloyd, A. ;
Rugman, P. ;
Newbold, Paul ;
Brightling, C. E. .
RESPIRATION, 2012, 83 (01) :36-44
[5]   Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis [J].
Bafadhel, Mona ;
Davies, Lisa ;
Calverley, Peter M. A. ;
Aaron, Shawn D. ;
Brightling, Christopher E. ;
Pavord, Ian D. .
EUROPEAN RESPIRATORY JOURNAL, 2014, 44 (03) :789-791
[6]   Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease A Randomized Placebo-Controlled Trial [J].
Bafadhel, Mona ;
McKenna, Susan ;
Terry, Sarah ;
Mistry, Vijay ;
Pancholi, Mitesh ;
Venge, Per ;
Lomas, David A. ;
Barer, Michael R. ;
Johnston, Sebastian L. ;
Pavord, Ian D. ;
Brightling, Christopher E. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (01) :48-55
[7]   Acute Exacerbations of Chronic Obstructive Pulmonary Disease Identification of Biologic Clusters and Their Biomarkers [J].
Bafadhel, Mona ;
McKenna, Susan ;
Terry, Sarah ;
Mistry, Vijay ;
Reid, Carlene ;
Haldar, Pranabashis ;
McCormick, Margaret ;
Haldar, Koirobi ;
Kebadze, Tatiana ;
Duvoix, Annelyse ;
Lindblad, Kerstin ;
Patel, Hemu ;
Rugman, Paul ;
Dodson, Paul ;
Jenkins, Martin ;
Saunders, Michael ;
Newbold, Paul ;
Green, Ruth H. ;
Venge, Per ;
Lomas, David A. ;
Barer, Michael R. ;
Johnston, Sebastian L. ;
Pavord, Ian D. ;
Brightling, Christopher E. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (06) :662-671
[8]  
Brightling C E, 2013, Ann Am Thorac Soc, V10 Suppl, pS214, DOI 10.1513/AnnalsATS.201302-023AW
[9]   Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial [J].
Brightling, CE ;
Monteiro, W ;
Ward, R ;
Parker, D ;
Morgan, MDL ;
Wardlaw, AJ ;
Pavord, ID .
LANCET, 2000, 356 (9240) :1480-1485
[10]   Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer [J].
Cedres, S. ;
Torrejon, D. ;
Martinez, A. ;
Martinez, P. ;
Navarro, A. ;
Zamora, E. ;
Mulet-Margalef, N. ;
Felip, E. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (11) :864-869